Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease

Jiao-Ya Xu, Zhong-Ping Li, Li Zhang, Guang Ji

Abstract
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and is one of the most prevalent liver disorders worldwide. NAFLD can gradually progress to liver inflammation, fibrosis, cirrhosis and even hepatocellular carcinoma. However, the pathogenesis of NAFLD is complex, and no efficient pharmacological treatments have yet been established for NAFLD. Accumulating data have shown that the farnesoid X receptor (FXR) plays important roles not only in bile acid metabolism, but also in lipid and carbohydrate homeostasis, inflammatory responses, among others. In this review, we aim to highlight the role of FXR in the pathogenesis and treatment of NAFLD.

Core tip: Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver disorders worldwide and has great risk potentials. While the mechanisms under NAFLD are still in the mist, farnesoid X receptor (FXR) provides a new aspect in this field. In addition to regulate bile acid metabolism, FXR can also be actively involved in lipid (cholesterol, triglyceride, fatty acid) and glucose metabolism, furthermore, FXR participates in regulating inflammation and NAFLD progression. Several FXR agonists are identified and both experimentally and clinically proved to be optimistic in preventing and treating NAFLD, indicating FXR quite a therapeutic target for NAFLD.

INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is characterized by the presence of lipid droplets in hepatocytes in the absence of alcohol consumption. The spectrum of NAFLD is from simple steatosis to non-alcoholic steatohepatitis (NASH) and eventually cirrhosis and hepatocellular carcinoma (HCC). NAFLD is affecting 15%-40% of the general population[1], and among them at least 10%-20% would develop to NASH[2], which is a potentially serious condition with poor prognosis. NASH is currently the most rapidly growing indication for liver transplantation (LT) in patients with HCC in the United States, and is predicted to become the leading indication for LT in the near future[3]. A recent large cohort study indicated that the prevalence of colorectal malignant neoplasm is also closely associated with NAFLD[4].
Frequently, NAFLD clusters with metabolic abnormalities, including type 2 diabetes, obesity, hypertension, hyperlipidemia, etc. Growing evidence has suggested that NAFLD is associated not only with liver-related mortality and morbidity but also with an increased incidence of chronic kidney disease, cardiovascular disease, and aortic valve sclerosis. NAFLD is thus becoming a major health issue. To date, no optimal treatment has been found, underscoring the need for further efforts in elucidating the pathogenesis of NAFLD and distinguishing effective pharmacological therapies.

Farnesoid X receptor (FXR) is a ligand-activated transcription factor belonging to the nuclear hormone receptor superfamily, it is abundantly expressed in the liver, intestine, kidney, and adrenal cortex, while low levels of FXR have been detected in a variety of tissues including the heart, lung, adipose tissue, etc. It was initially thought to be the receptor of intermediate metabolites, farnesol, from which the name “Farnesoid X receptor” was derived. In 1999, bile acids (BAs) were found as the natural ligands of FXR, which has since been known as bile acid receptor. As a transcription factor, it binds to DNA either as a monomer or as a heterodimer with a common partner-retinoid X receptor (RXR) to regulate the expression of various genes involved in BA, lipid and glucose metabolism.

It has been observed that hepatic expression of FXR is decreased in NAFLD patients, which is associated with hepatic triglyceride (TG) accumulation and hepatic steatosis. FXR deficiency animal models display hepatic steatosis, hyperlipidaemia, hyperglycemia, BA overload, inflammation and fibrosis. However, these can be improved by FXR activation, indicating FXR could be a key regulator of metabolic homeostasis. Thus FXR appears to be a promising target for the treatment of NAFLD.

**POTENTIAL PATHOGENESIS OF NAFLD**

The pathogenesis and progression of NAFLD are multifactorial and not quite so clear, while generally explained by the “two-hit” theory. The “first hit” is hepatic fat accumulation owing to increased hepatic de novo lipogenesis (DNL) and fatty acid uptake, inhibition of fatty acid β oxidation (FAO), impaired TG clearance and decreased very-low-density lipoprotein (VLDL) export. Oxidative stress and subsequent inflammation are key factors of the “second hit”, which ultimately cause further liver damage. Studies have shown that multiple parallel hits, including genetic differences, intestinal microbiota, adipose-derived cytokines and so on account for the progression of NAFLD.

Loss of the body’s ability to retain excess lipids in “classical” adipose tissue stores can lead to the overdevelopment of ectopic fat deposition, often creating severe perturbations of both glucose and lipid homeostasis. Excessive fat accumulation in the liver is recognized as a pathological state. Hepatic ectopic fat deposition, especially TG, cholesterol and fatty acid eventually lead to disordered hepatic lipid metabolism.

TG derives from the esterification of free fatty acid (FFA) that may come from dietary fats, adipose tissue and DNL, and can be used for energy through FAO in mitochondria. Hepatic TG lipolysis is mediated by lipases, which release FFA for oxidation. After synthesis, hepatic TG may be stored as lipid droplets or packaged with ApoB into VLDL and then secreted into circulation.

**MECHANISMS OF FXR IN NAFLD**

Although inappropriate lipid metabolism, insulin resistance, and inflammation represent important risk factors for the development of NAFLD, the precise mechanisms controlling disease pathogenesis remain largely undefined. Recent studies on FXR have provided new opportunities to elucidate the pathogenesis of NAFLD, and the beneficial role of FXR on NAFLD is through multiple mechanisms.

**FXR in regulating bile acid metabolism**

BAs are the end products of cholesterol catabolism, produced in the liver, then secreted into the bile canaliculi and subsequently stored in the gall bladder. After ingestion of food, bile flows into the duodenum, where it contributes to the absorption of dietary lipid and fat-soluble vitamins. Most of these BAs (95%) are then reabsorbed from the terminal ileum and transported back to the liver via the portal vein, which is known as enterohepatic circulation. Only about 5% of them escapes from reabsorption per cycle and expels from the body in the feces.

BA synthesis via two different pathways: the classical pathway and alternative pathway. Two primary BAs cholic acid (CA), chenodeoxycholic acid (CDCA) are the end products of these two pathways. Secondary BAs deoxycholic acid (DCA) and lithocholic acid (LCA) are derived from primary BAs in the intestine by bacterial enzymes.

Three enzymes play major regulatory roles in these two pathways. Cholesterol 7α-hydroxylase (CYP7A1) is the rate-limiting enzyme in the classical pathway, whereas sterol-27 hydroxylase (CYP27A1) is the first enzyme in the alternative pathway, followed by sterol 12α-hydroxylase (CYP8B1). Several members participate in bile acid transport and enterohepatic circulation. The bile salt export pump (BSEP) is mainly responsible for bile acid transport at the canalicular membrane. Na+-dependent taurocholate transporter (NTCP) is responsible for basolateral bile acid transport into the hepatocytes. BAs are reabsorbed mostly in the terminal ileum, and are mainly mediated by the apical sodium-dependent bile salt transporter (ASBT). Once absorbed into the enterocytes, BAs then bind the intestinal bile acid binding protein (1-BABP) and are transported to the basolateral membrane for secretion.

Although BAs have many physiological roles, abnormal high levels of BAs would increase the risk of hepatotoxicity, because they can cause oxidative stress,
FXR plays a central role in bile acid homeostasis by regulating genes involved in bile acid synthesis, secretion and reabsorption. FXR inhibits de novo BA biosynthesis through up-regulation of the small heterodimer partner (SHP), which interacts with and represses the transcriptional activator, liver related homolog 1 (LRH-1) and hepatocyte nuclear factor-4α (HNF-4α), thus bind to the CYP7A1 gene promoter, and inhibiting CYP7A1 gene transcription\[33,34\]. Additionally, FXR can induce intestinal fibroblast growth factor 19 (FGF19) in humans, as well as FGF15, the mouse ortholog of human FGF19, which then activate the cell-surface receptor, FGF receptor 4 (FGFR4), to eventually inhibit CYP7A1 gene transcription and bile acid synthesis intracellular via intracellular Jun N-terminal kinase (JNK) pathway\[33-34\]. FXR encompasses the regulation of the enterohepatic circulation. Through up-regulation of BSEP and multidrug resistance protein 2 (MRP2, human canalicular bilirubin conjugate export pump) and inhibition of NTCP, FXR reduces hepatocellular BA levels by stimulating bile acid secretion at the canalicular membrane and limit bile acid uptake from the portal circulation\[37-39\]. FXR is also able to induce alternative basolateral BA transport through organic solute transporter α/β (OSTa/β), to efflux BAs to systemic circulation and, subsequently, are eliminated by renal excretion\[38,69\]. Given the above, FXR regulates the synthesis and export of BAs, hence activation of FXR can protect against the liver from toxic accumulation of BAs.

**FXR on cholesterol metabolism**

In recent years, the role of FXR in cholesterol metabolism has been widely explored. Emerging experimental and clinical evidence has linked altered hepatic cholesterol homeostasis and free cholesterol (FC) accumulation to the risk and severity of NAFLD and the pathogenesis of NASH\[50\]. It is considered that hepatic accumulation of cholesterol rather than TG may play a critical role in the NAFLD progression\[22\].

In hepatocytes, cholesterol homeostasis pathways include cholesterol de novo synthesis, uptake in the form of low density lipoprotein (LDL) and chylomicron remnants, excretion into the blood in the form of VLDL, excretion and uptake through bile, and synthesis of BAs and their excretion\[42\]. Since FXR is a key regulator of bile acid metabolism, it is also critical in maintaining cholesterol homeostasis. FXR deficiency mice display increased levels of hepatic and serum cholesterol\[43,44\], and FXR negatively regulates cholesterol levels via various mechanisms.

LDL receptor (LDLR), the scavenger receptor class B type I (SR-BI) and cluster differentiation protein-36 (CD-36) are involved in hepatic cholesterol uptake. Increased LDLR and CD-36 expression, and decreased SR-BI expression are detected in NAFLD, which correlates with the severity of steatosis\[40\]. Activation of FXR represses the expression of proprotein convertase subtilisin/kexin type 9 (PCSK9), an inhibitor of LDLR, thus increases LDLR activity, and potentiates the hypolipidemic effect of statins\[40\]. SR-BI is critical for reverse cholesterol transport by transporting high-density lipoprotein (HDL) cholesterol into liver where a part of the cholesterol is metabolized to BAs\[7,48\]. FXR null mice exhibit reduced SR-BI expression\[44\]. A recent study showed that FXR positively regulates SR-BI expression, and three binding sites in the first intron of the SR-BI gene were identified\[47\]. Meanwhile, FXR induced reduction of CD36 also effectively prevents liver from steatosis\[41\]. In the liver, FXR enhances ATP-binding cassette G member 5 and member 8 (ABCG5/G8) expression, a heterodimeric cholesterol efflux transporter, which accounts for increased cholesterol excretion\[80\]. Collectively, FXR inhibits cholesterol uptake and synthesis and promotes cholesterol excretion, eventually improves cholesterol overload.

**FXR in mediating fatty acid and triglyceride metabolism**

Hepatic steatosis is the hallmark of NAFLD due to an imbalance between TG synthesis and clearance. From a liver centric point of view, this imbalance results from abnormalities in one or more of the following four processes: (1) hepatic uptake of fatty acid, lipoprotein and glucose; (2) de novo TG synthesis; (3) TG degradation and FAO; and (4) lipoprotein secretion in the form of VLDL\[39\].

FXR has shown considerable impact on lipogenesis. Hepatic lipogenesis is mainly regulated by sterol regulatory element binding protein 1c (SREBP-1c), which is known as the master regulator of lipid biosynthesis and regulates the expression of several genes involved in lipogenesis\[53\]. FXR activation can inhibit the expression of SREBP-1c and its target enzymes, such as fatty acid synthase (FAS), stearoyl-coenzyme A desaturase 1 (SCD-1) and acetyl-CoA carboxylase (ACC), and prevent excessive fatty acid synthesis and overproduction of TG\[19,53,54\]. FXR null mice develop hepatic steatosis and hypertriglyceridemia\[53\]. In NAFLD patients, decreased expression of hepatic FXR also displays elevated TG synthesis, due to increased expression of SREBP-1c and its target enzymes, such as fatty acid synthase (FAS), stearoyl-CoA desaturase 1 (SCD-1) and acetyl-CoA carboxylase (ACC), and prevent excessive fatty acid synthesis and overproduction of TG\[53,54\]. Other mechanisms independent of the FXR-SHP-SREBP-1c pathway may also contribute to FXR-mediated TG homeostasis\[19,53,54\].

FXR also demonstrates an ability to enhance TG clearance. FXR is known to induce apolipoprotein C-II (Apo C-II) and apolipoprotein AIV (Apo AIV) and inhibit apolipoprotein C-III (Apo C-III) and angioptoinetlike 3 expression, thus activating lipoprotein lipase (LPL)-
mediated lipolysis of TG rich lipoproteins\cite{56}. Peroxisome proliferator-activated receptor alpha (PPARα) is a key regulator of FAO and activation of FXR induces the expression of PPARα and its target gene, carnitine palmitoyltransferase 1 (CPT1), the rate-limiting enzyme in FAO\cite{67}. Furthermore, FXR activation by natural and synthetic BAs increases the expression and secretion of fibroblast growth factor 21 (FGF21), which has been reported to profoundly reduce hepatic TG levels via inhibition of SREBP-1c\cite{58,59,60}. Furthermore, FGF21 induces gluconeogenesis, FAO, and ketogenesis in the liver\cite{68}.

In addition, FXR-induced hepatic expression of aldo-keto reductase B7 (Akr1b7) has revealed a striking effect on ameliorating hepatic lipid accumulation in db/db mice\cite{61}. A recent study showed that hepatic carboxylesterase 1 (CES1) plays a key role in regulating both normal and FXR-controlled lipid homeostasis. Overexpression of hepatic CES1 lowered hepatic TG, while knockdown of hepatic CES1 increased hepatic TG and plasma cholesterol levels. These effects likely resulted from the TG hydrolase activity of CES1. Activation of FXR induced hepatic CES1, and reduced the levels of hepatic and plasma TG as well as plasma cholesterol in a CES1-dependent manner\cite{62}. Lu \textit{et al.}\cite{63} have identified YY1 as a novel transcription factor involved in hepatic TG metabolism in obesity. YY1 expression is markedly up-regulated in HFD-induced obese mice and NAFLD patients. YY1 suppresses FXR expression \textit{via} interaction with the YY1 binding site at the first intron of the FXR gene. Liver-specific ablation of YY1 ameliorates liver TG accumulation in obese mice.

\textbf{FXR and inflammation}

Inflammation and fibrosis are main pathological manifestations of NASH. Recently, it has become clear that FXR can down-regulate genes involved in inflammation. FXR deficiency is considered as a significant risk factor in the development of NASH. LDLR\textsuperscript{-/-}/FXR\textsuperscript{-/-} mice fed a high-fat diet (HFD) display higher levels of pro-inflammatory and pro-fibrogenic cytokines, such as tumor necrosis factor α (TNFα), intercellular adhesion molecule-1 (ICAM-1), α-smooth muscle actin (α-SMA), tissue inhibitor of metalloproteinase (TIMP)-1, transforming growth factor (TGFβ), procollagen 1α1 and type 1 collagen compared to LDLR\textsuperscript{-/-}/FXR\textsuperscript{+/+} mice\cite{64}. These studies indicated that activation of FXR may be a therapeutic target in curing NASH.

Indeed, FXR activation appears to protect mice against methionine and choline-deficient (MCD) diet-induced NASH. The reduction in inflammatory cell infiltration and hepatic fibrosis correlated with decreased levels of hepatic inflammation markers such as keratinocyte-derived chemokine (mKC), MCP-1, VCAM-1, etc, and fibrosis markers such as TIMP-1, α1(I) collagen, α-SMA, TGF-β1, matrix metalloproteinase 2 (MMP-2) and α2(I) collagen\cite{65}. Furthermore, the observation that FXR null mice are more susceptible to LPS-induced liver injury, indicating a direct anti-inflammatory role of FXR, which has been explained \textit{via} negatively mediating the nuclear factor kappa-B (NF-κB) pathway\cite{66}. Additionally, in the intestine, FXR is required to improve biliary obstruction, inhibit bacterial overgrowth, mucosal injury and bacterial translocation\cite{67}. Another anti-inflammatory effect of FXR involves induction of suppressor of cytokine signaling 3 (SOCS3) that inhibits signal transducer and activator of transcription (STAT3) signaling\cite{68}. Recently, Peng \textit{et al.}\cite{69} identified RECK, a membrane-anchored inhibitor of MMP-9, as a novel target gene of FXR in mouse liver. Whether the FXR agonist attenuates hepatic inflammation and fibrosis in a mouse NASH model through the FXR-RECK-MMP-9 cascade still needs further investigation. On the other hand, cholesterol over-intake and BAs accumulation are correlated with the onset and severity in NASH, while the role of FXR in the process need to be further clarified\cite{70}.

Some microRNAs have been found to be target genes of FXR, and regulate the process of liver fibrogenesis. FXR-mediated miR-29a up-regulation in hepatic stellate cells (HSCs) leads to decreased amounts of extracellular matrix, and thus protects against liver fibrosis\cite{71}. In another study, liver tissues from patients with severe fibrosis are found to have lower levels of FXR and liver kinase B1 (LKB1) with up-regulated miR-199a-3p. FXR is further confirmed to protect hepatocytes from injury by repressing miR-199a-3p and thereby increasing levels of LKB1\cite{72,73}. Taken together, the anti-inflammatory actions of FXR are obtained from intra-hepatic and extra-hepatic mechanisms, more experiments are needed to elucidate the molecular mechanisms under the actions.

\textbf{Other possible mechanisms}

Type 2 diabetes is an established risk factor for development of hepatic steatosis and NAFLD. Indeed, the prevalence of NAFLD is higher in patients with type 2 diabetes\cite{74}. Several animal studies have shown that FXR activation can improve insulin sensitivity and down-regulate phosphoenolpyruvate kinase (PEPCK) and glucose-6-phosphatase (G-6-Pase), two key enzymes in gluconeogenesis\cite{75,76}. Activation of FXR is also reported to induce the phosphorylation of glycogen synthase kinase 3β (GSK3β) to enhance glycogen storage in db/db mice\cite{77}. FXR also has a novel role in promoting liver regeneration/repair after liver damage, including physical resection or toxic injury\cite{78}. From this research, has addressed the role of FXR on oxidative stress. FXR-null mice generated enhanced oxidative stress, which may be attributable to a continuously high level of hepatic BAs. On the other hand, FXR activation appeared to repress CYP2E1 expression and attenuate oxidative stress, thus ameliorating liver injury in a murine model of alcoholic liver disease (ALD)\cite{79,80}. FXR is proved to have anti-atherosclerotic effects as well\cite{81}. Recently, down-regulation of hepatic FXR expression by endoplasmic reticulum (ER) stress has been proposed to be in close association with aging-induced fatty liver in mice, mainly through inhibition of hepatocyte nuclear factor 1 alpha (HNF1α).
transcriptional activity\textsuperscript{[58]}. In general, these findings suggest extra mechanisms of FXR in treating NAFLD.

**FXR AGONISTS IN TREATING NAFLD**

Up to date, no efficient treatments are available for management of NAFLD. As FXR plays critical roles in mediating metabolic homeostasis and inhibiting inflammatory response, it is emerging as an ideal target for treatment of NAFLD. Numerous natural, semisynthetic, and synthetic FXR agonists have shown protective role in animal models and patients with NAFLD.

GW4064 is a non-steroidal synthetic FXR agonist. Activation of FXR by GW4064 suppressed weight gain and attenuated hepatic inflammation in C57BL/6 mice fed with either HFD or high-fat and high-cholesterol diet. GW4064 treatment also repressed diet-induced hepatic steatosis as evidenced by lower TG and FFA level in the liver, possibly due to markedly reduced lipid transporter CD36 expression. In this model, GW4064 improved hyperinsulinemia and hyperglycemia via decreasing PEPCK and G6Pase\textsuperscript{[40]}. Adiponectin and its receptors are two important factors in treatment of NAFLD. A recent study showed that treatment of GW4064 can up-regulate the expression of PPARγ2, adiponectin, adiponectin receptor 2 (adipoR2) in 3T3-L1 preadipocytes and adipoR2 in HepG2 cells, indicating that FXR agonist has a therapeutic potential in NAFLD\textsuperscript{[77]}. GW4064 strongly induced FGF19 and inhibit CYP7A1, in which the hepatic FGF19/FGFR4/Erk1/2 pathway played a key role, which is independent of SHP. In addition to inducing FGF19 in the intestine, BAs in hepatocytes may activate the liver FGF19/FGFR4 signaling pathway to inhibit BA synthesis and prevent accumulation of toxic bile acid in human livers\textsuperscript{[50]}.

Obeticholic acid (OCA or INT-747, 6α-ethylchenodeoxycholic acid) is a semisynthetic derivative of the primary human bile acid chenodeoxycholic acid, and the natural agonist of FXR. Administration of OCA reversed hepatic steatosis and insulin resistance in Zucker (fa/fa) obese rats, protecting against body weight gain and fat deposition in liver and muscle, due to FXR-induced lipogenesis and gluconeogenesis decrease\textsuperscript{[49]}. OCA can inhibit NF-κB-mediated hepatic inflammation, however, the anti-inflammatory effect of OCA are not liver-specific, OCA treatment may also reduce intestinal inflammation and permeability in experimental models of colitis\textsuperscript{[78]}. Also, in primary rat HSCs, 6E-CDCA reduced thrombin-induced up-regulation of α1 (I) collagen, α-SMA and TIMP-1/2 mRNA expression and protected against fibrosis\textsuperscript{[19]}. In a phase 2 clinical trial in patients with type 2 diabetes mellitus and NAFLD (ClinicalTrials.gov, No. NCT00501592), administration of 25 or 50 mg OCA for 6 wk was well tolerated. OCA was found to increase insulin sensitivity and significantly decrease levels of γ-glutamyltransferase and alanine aminotransferase (ALT). Markers of liver inflammation and fibrosis were also decreased in these patients\textsuperscript{[83]}.

WAY-362450, a synthetic potent FXR agonist, could attenuate hepatic inflammation and fibrosis in MCD diet induced NASH mice\textsuperscript{[20]}. WAY-362450 treatment was also found to attenuate oxidative stress in a murine model of ALD\textsuperscript{[78]}. Furthermore, treatment of obese db/db mice with INT-767, a dual FXR/TGR5 (a G-protein-coupled bile acid receptor) agonist, significantly improved the histologic features of NASH, resulted from recruitment of anti-inflammatory Ly6C\textsuperscript{low} monocytes to the liver, directly down-regulated the expression of Ly6C on bone-marrow derived monocytes and decreased production of pro-inflammatory cytokines by macrophages. In addition, INT-767 increased interleukin (IL)-10 production and enhanced hepatic expression of genes associated with alternatively activated macrophages. The data suggested INT-767 as a potential treatment target of NAFLD due to coordinating the immune phenotype of monocytes and macrophages\textsuperscript{[81]}. In another study, INT-767 treatment markedly decreased cholesterol and TG levels in diabetic mice\textsuperscript{[82]}.

**CONCLUSION**

The data presented suggest that FXR plays crucial roles in mediating multiple target genes associated with bile acid, lipid and glucose metabolism and has beneficial effects on inflammation response, thus can partly interpret the pathogenesis of NAFLD. Accumulative data prove that targeting FXR may be beneficial in the prevention and treatment of NAFLD. However, some reports showed opposite effects. For instance, the role of FXR in regulating HDL metabolism is still under debate, and need to be further evaluated. Some studies demonstrated different results, as FXR−/− mice had increased plasma HDL-cholesterol\textsuperscript{[44]}, and blockage of FXR activity also displayed reduced serum LDL levels and increased HDL levels\textsuperscript{[84]}, while activation of FXR by GW4064 suppressed apolipoprotein A-I transcription and reduced serum HDL levels\textsuperscript{[86]}. On the other hand, FXR deficiency was shown to protect from excessive body weight gain in both genetic (ob/ob) and diet-induced obesity murine models and improve hyperglycemia and impaired glucose tolerance\textsuperscript{[85]}. The same result also emerged in aging FXR deficient mice, and the reduced body weight gain is most likely explained by the increased energy expenditure\textsuperscript{[13]}. In line with this, another study showed that activation of FXR with GW4064 was not useful for long term management of the metabolic syndrome, as it reduced the BA pool size and subsequently decreased energy expenditure, translating as weight gain and insulin resistance\textsuperscript{[86]}.

In summary, research on FXR has provided new opportunities to elucidate the pathogenesis of NAFLD and to develop effective treatment. Although activation of FXR by specific agonists could be an attractive pharmacological strategy for managing NAFLD, attention needs to be paid to several undesirable contradictory results, which remain to be elucidated. Since most evidence comes from preclinical studies, more clinical evidence is
urgently needed to establish treatments of FXR agonists for NAFLD.

REFERENCES

1 Kwok R, Tse YK, Wong GL, Ha Y, Lee AU, Ngu MC, Chan HL, Wong VW. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease—the role of transient elastography and plasma cytookeratin-18 fragments. *Aliment Pharmacol Ther* 2014; 39: 254-269 [PMID: 24308774 DOI: 10.1111/apt.12569]

2 Sanjay AJ. NASH: A global health problem. *Hepatol Res* 2011; 41: 670-674 [PMID: 21711426 DOI: 10.1111/j.1872-034X.2011.00824.x]

3 Wong RJ. Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. *Hepatology* 2014; 59: 2188-2195 [PMID: 24375711 DOI: 10.1002/hep.26986]

4 Lin XF, Shi KQ, You J, Liu WY, Luo YW, Wu FL, Chen YP, Wong DK, Yuen MF, Zheng MH. Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease: a large study. *Mol Biol Rep* 2014; 41: 2899-2997 [PMID: 24449368 DOI: 10.1007/s11033-014-3157-y]

5 El Azeem HA, Kong B, Luyendyk JP, Tawfik O, Guo GL. Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. *J Pharmacol Exp Ther* 2009; 328: 116-122 [PMID: 18948847 DOI: 10.1124/jpet.108.144600]

6 Ma K, Saha PK, Chan L, Moore DD. Farnesoid X receptor is essential for normal glucose homeostasis. *J Clin Invest* 2006; 116: 1102-1109 [PMID: 16557297 DOI: 10.1172/JCI25604]

7 Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, Moore DD, Auwerx J. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. *J Clin Invest* 2004; 113: 1408-1418 [PMID: 15146289 DOI: 10.1172/JCI20125]

8 Cipriani S, Mencarelli A, Palladino G, Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. *J Lipid Res* 2010; 51: 771-784 [PMID: 19783811 DOI: 10.1194/jlr.M011602]

9 Zhang S, Wang J, Liu Q, Harnish DC. Farnesoid X receptor agonist WAY-326450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. *J Hepatol* 2009; 51: 380-388 [PMID: 19501927 DOI: 10.1016/j.jhep.2009.03.025]

10 Day CP, James OF. Steatohepatitis: a tale of two “hits”? *Gastroenterology* 1998; 114: 842-845 [PMID: 9547102]

11 Nomura K, Yamanouchi T. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. *J Nutr Biochem* 2012; 23: 203-208 [PMID: 22212869 DOI: 10.1016/j.jnutbio.2011.09.006]

12 Mantena SK, King AL, Andringa KG, Eccleston HB, Bailey SM. Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases. *Free Radic Biol Med* 2008; 44: 1259-1272 [PMID: 18242193 DOI: 10.1016/j.freeradbiomed.2007.12.029]

13 Lanktree MB, Johansen CT, Joy TR, Hegele RA. A translational view of the genetics of lipodystrophy and ectopic fat deposition. *Prog Mol Biol Transl Sci* 2010; 94: 159-196 [PMID: 21036325 DOI: 10.1016/S1177-1733(10)49006-4]

14 Li Y, Jadhav K, Zhang Y. Bile acid receptors in non-alcoholic fatty liver disease. *Biochem Pharmacol* 2013; 86: 1517-1524 [PMID: 23988487 DOI: 10.1016/j.bcp.2013.08.015]

15 Rizzo G, Renga B, Mencarelli A, Pellicciani R, Fiorucci S. Role of FXR in regulating bile acid homeostasis and relevance for human diseases. *Curr Drug Targets Immune Endocr Metabol Disord* 2005; 5: 289-303 [PMID: 16178789]

16 Li T, Chiang JY. Bile Acid signaling in liver metabolism and diseases. *J Lipids* 2012; 7: 574067 [PMID: 21991404 DOI: 10.1155/2012/754067]

17 Allen K, Jaeschke H, Copple BL. Bile acids induce inflammatory mediators in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. *Am J Pathol* 2011; 178: 175-186 [PMID: 21224055 DOI: 10.1016/j.ajpath.2010.11.026]

18 Hofmann AF. The continuing importance of bile acid transporters in liver and intestinal disease. *Arch Intern Med* 1999; 159: 2647-2658 [PMID: 10597755]

19 Chiang JY. Bile acid metabolism and signaling. *Compr Physiol* 2013; 3: 1191-1212 [PMID: 23897684 DOI: 10.1002/cphy.c120023]

20 Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, Galardi C, Wilson JC, Lewis MC, Roth ME, Maclennan PR, Willson TM, Kliwer SA. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. *Mol Cell* 2000; 6: 517-526 [PMID: 11030332 DOI: 10.1016/S1097-2765(00)00051-4]

21 Chiang JY. Bile acid regulation of gene expression: roles of nuclear hormone receptors. *Endocr Rev* 2002; 23: 443-463 [PMID: 12202460 DOI: 10.1210/er.2000-0035]

22 Chen Q, Jiang Y, An Y, Zhao N, Zhao Y, Yu C. Soluble FGFR4 extracellular domain inhibits FGFR19-induced activa-
tion of FGF4/RA signaling and prevents nonalcoholic fatty liver disease. Biochim Biophys Acta 2011; 1810: 651-656 [PMID: 21616061 DOI: 10.1016/j.bbamcr.2010.05.059]

34 Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald RG, Luo G, Jones SA, Goodwin B, Richardson JA, Gerard RD, Repa JJ, Mangelsdorf DJ, Kliewer SA. Fibroblast growth factor 15 functions as an enterohormone signal to regulate bile acid homeostasis. Cell Metab 2005; 2: 217-225 [PMID: 16213244 DOI: 10.1016/j.cmet.2005.09.001]

35 Song KH, Li T, Owsley E, Strom S, Chiang YJ. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7α-hydroxylase gene expression. Hepatology 2009; 49: 297-305 [PMID: 19085950 DOI: 10.1002/hep.22627]

36 Eloranta JJ, Kullak-Ublick GA. The role of FXR in disorders of bile acid homeostasis. Physiology (Bethesda) 2008; 23: 286-295 [PMID: 18927204 DOI: 10.1152/physiol0020.2008]

37 Geier A, Wagner M, Dietrich CG, Trauner M. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim Biophys Acta 2007; 1773: 283-308 [PMID: 17291602 DOI: 10.1016/j.bbamac.2006.04.014]

38 Pollheimer MJ, Fickert P, Stieger B. Chronic cholestatic liver diseases: clues from histopathology for pathogenesis. Mol Aspects Med 2014; 35: 35-56 [PMID: 24141039 DOI: 10.1016/j.mam.2013.10.001]

39 Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM, Tomontoz P, Kliewer S, Willson TM, Edwards PA. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 2002; 277: 2908-2915 [PMID: 11706036 DOI: 10.1016/j.jbc.2002.05.001]

40 Boyler JN, Trauner M, Mennone A, Soroka CJ, Cai SY, Moustafa T, Zollner G, Lee JY, Ballatori N. Upregulation of bile acid homeostasis.

41 Musso G, Gambino R, Cassader M. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog Lipid Res 2013; 52: 175-191 [PMID: 23260728 DOI: 10.1016/j.jplres.2012.11.002]

42 Enjoji M, Yasutake K, Kohjima M, Nakamura M. Nutrition and nonalcoholic fatty liver disease: the significance of cholesterol. Int J Hepatol 2012; 2012: 928607 [PMID: 22585922 DOI: 10.1155/2012/928607]

43 Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ, Zhang Z, Xiao C, Yu D. Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance. Pharm Res 2013; 30: 1447-1457 [PMID: 23371517 DOI: 10.1007/s11195-013-0986-7]

44 Li T, Malezol M, Boehme S, Kong B, Nilsson LM, Guo G, Ellis E, Chiang YJ. Overexpression of cholesterol 7α-hydroxylase promotes hepatic bile acid synthesis and secretion and maintains cholesterol homeostasis. Hepatology 2011; 53: 996-1006 [PMID: 21319191 DOI: 10.1002/hep.24107]

45 Jiang ZG, Rosbin SC, Yao Z. Lipoprotein metabolism in nonalcoholic fatty liver disease. J Biomed Res 2013; 27: 1-13 [PMID: 23545788 DOI: 10.7555/JBR.27.20120077]

46 Horton JD, Goldstein JL, Brown MS. SREBP's: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-1131 [PMID: 11994699 DOi: 10.1172/JCI115993]

47 Xiong X, Wang X, Lu Y, Wang E, Zhang Z, Yang J, Zhang H, Li X. Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice. J Hepatol 2014; 60: 847-854 [PMID: 22333182 DOI: 10.1016/j.jhep.2013.12.003]

48 Li X, Li Y, Yang W, Xiao C, Fu S, Deng Q, Ding H, Wang Z, Liu G, Li X. SREBP-1c overexpression induces triglycerides accumulation through increasing lipid synthesis and decreasing lipid oxidation and VLDL assembly in bovine hepatocytes. J Steroid Biochem Mol Biol 2014; 143: 174-182 [PMID: 24565651 DOI: 10.1016/j.jsbmb.2014.02.009]

49 Trauner M, Claudel T, Fickert P, Moustafa T, Wagner M. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis 2010; 28: 220-224 [PMID: 20469015 DOI: 10.1159/000280291]

50 Fuchs M. Non-alcoholic Fatty liver disease: the bile Acid-activated farnesoid x receptor as an emerging treatment target. J Lipids 2012; 2012: 934936 [PMID: 22187656 DOI: 10.1155/2012/934936]

51 Pineda Torra I, Claudel T, Duval C, Koskykh V, Fruchart JC, Staels B. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid x receptor. Mol Endocrinol 2003; 17: 259-272 [PMID: 12554753 DOI: 10.1209/mee.2002.0120]

52 Cyphert HA, Ge X, Kohan AB, Salati LM, Zhang Y, Hill-gartner FB. Activation of the farnesoid x receptor induces hepatic expression and secretion of fibrolast growth factor 21. J Biol Chem 2012; 287: 25123-25138 [PMID: 22661717 DOI: 10.1074/jbc.M112.375907]

53 Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, Vonderfecht S, Hecht R, Li YS, Lindberg RA, Chen JL, Jung DY, Zhang Z, Ko HJ, Kim JK, Véniant MM. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009; 58: 250-259 [PMID: 18840786 DOI: 10.2373/dh08-0392]

54 Seo JA, Kim NH. Fibrolast growth factor 21: a novel metabolic regulator. Diabetes Metab J 2012; 36: 26-28 [PMID: 22363918 DOI: 10.4093/dmj.2012.36.1.26]

55 Xu J, Yin L, Ma H, Li T, Chiang YJ, Zhang Y. Aldo-keto reductase 18β is a target gene of FXR and regulates lipid and glucose homeostasis. J Lipid Res 2011; 52: 1561-1568 [PMID: 21642744 DOI: 10.1194/jlr.M015859]

56 Xu J, Li Y, Chen WD, Xu Y, Yin L, Ge X, Jadhav K, Adorni L, Zhang Y. Hepatic carboxylesterase 1 is essential for both normal and farnesoid x receptor-controlled lipid homeostasis. Hepatology 2014; 59: 1761-1771 [PMID: 24038130 DOI: 10.1002/hep.26714]

57 Lu Y, Ma Z, Zhang Z, Xiong X, Wang X, Zhang H, Shi G, Xia X, Ning G, Li X. Yin Yang 1 promotes hepatic steatosis through

Xu JY et al. Recent insights into FXR in NAFLD
Roles of microRNA-29a in the antifibrotic effect of farnesoid X receptor (FXR) agonist obeticholic acid in obese mice. *Hepatology* 2011; 53: 170-178 [PMID: 21634943 DOI: 10.1002/hep.2463129]

Fiorucci S, Rizzo G, Antonelli E, Renga B, Mencarelli A, Riccardi L, Orlandi S, Pruzzanski M, Morelli A, Pelliccari R. A farnesoid X receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. *J Pharmacol Exp Ther* 2005; 314: 584-595 [PMID: 15860571 DOI: 10.1124/jpet.104.069405]

Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HM, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe D, Dillon P, Pruzzanski M, Shapiro D. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. *Gastroenterology* 2013; 145: 574-582.e1 [PMID: 23727264 DOI: 10.1053/j.gastro.2013.05.042]

McMahan RH, Wang XX, Cheng LL, Krisko T, Smith M, El Kasni K, Pruzzanski M, Adorini L, Golden-Mason L, Levi M, Rosen HR. Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. *J Biol Chem* 2013; 288: 11761-11770 [PMID: 24360643 DOI: 10.1074/jbc.M112.446575]

Rizzo G, Passeri D, De Franco F, Ciaccioli G, Donadio L, Rizzo G, Orlandi S, Sadeghpour B, Wang XX, Jiang T, Levi M, Pruzzanski M, Adorini L. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. *Mol Pharmacol* 2010; 78: 617-630 [PMID: 20631053 DOI: 10.1124/mol.110.064501]

Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, Gonzalez FJ, Heyman RA, Mangelsdorf DJ, Moore DD. A natural product that lowers cholesterol as an antagonist ligand for FXR. *Science* 2002; 296: 1703-1706 [PMID: 11988557 DOI: 10.1126/science.1072891]

Claudel T, Sturm E, Duez H, Torra IP, Sirvent A, Kosykh V, Arita E, Mataki C, Sato H, Tanigawara Y, Schoonjans K, Itoh N, Brennan MC, Chao C, Gadaleta RM, van Mil SW. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. *Gut* 2011; 60: 463-472 [PMID: 21242261 DOI: 10.1136/gut.2010.212199]

Watanabe M, Horai Y, Houten SM, Morimoto K, Sugizaki T, Arita E, Matakis C, Sato H, Tanigawara Y, Schoonjans K, Itoh H, Auwerx J. Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure. *J Biol Chem* 2011; 286: 26913-26920 [PMID: 21632533 DOI: 10.1074/jbc.M111.248203]

P-Reviewer: He ST, Lau WY S-Editor: Ding Y L-Editor: O'Neill M E-Editor: Wang CH

Xu JY et al. Recent insights into FXR in NAFLD

repression of farnesoid X receptor in obese mice. *Gut* 2014; 63: 170-178 [PMID: 23349861 DOI: 10.1136/gutjnl-2012-303150]

Wang YD, Chen WD, Wang M, Yu D, Forman BM, Huang W. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. *Hepatology* 2008; 48: 1632-1643 [PMID: 18972444 DOI: 10.1002/hep.22259]

Inagaki T, Moschetta A, Lee YK, Peng L, Zhao G, Downes M, Yu RT, Shelton JM, Richardson JA, Repa JJ, Mangelsdorf DJ, Kliewer SA. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. *Proc Natl Acad Sci USA* 2006; 103: 3920-3925 [PMID: 16743964 DOI: 10.1073/pnas.0509992103]

Xu Z, Huang G, Gong W, Zhou P, Zhao Y, Zhang Y, Zeng Y, Gao M, Pan Z, He F. FXR ligands protect against hepatocellular inflammation via SOCS3 induction. *Cell Signal* 2012; 24: 1658-1664 [PMID: 22560881 DOI: 10.1016/j.cellsig.2012.04.015]

Peng X, Wu W, Zhu B, Sun Z, Li L, Ruan Y, Zhou M, Duj, Gu J. Activation of farnesoid X receptor induces RECK expression in mouse liver. *Biochem Biophys Res Commun* 2014; 443: 211-216 [PMID: 24291900 DOI: 10.1016/j.bbrc.2013.11.082]

Jia X, Naito H, Yetti H, Tamada H, Kitamori K, Hayashi Y, Wang D, Yanagiba Y, Wang J, Ieda K, Yamori Y, Nakajima T. Dysregulated bile acid synthesis, metabolism and excretion in a high fat-cholesterol diet-induced fibrotic steatohepatitis in rats. *Dis Dig Sci* 2013; 58: 2212-2222 [PMID: 23824403 DOI: 10.1007/s10620-013-2347-1]

Li J, Zhang Y, Kuruba R, Gao M, Xiong J. Roles of microRNA-29a in the antifibrotic effect of farnesoid X receptor in hepatic stellate cells. *Mol Pharmacol* 2011; 80: 191-200 [PMID: 21511916 DOI: 10.1124/mol.110.068247]

Lee CG, Kim YW, Kim EH, Meng Z, Huang W, Hwang SJ, Kim SG. Farnesoid X receptor protects hepatocytes from injury by repressing miR-199a-3p, which increases levels of LKB1. *Gastroenterology* 2012; 142: 1206-1217.e7 [PMID: 22269968 DOI: 10.1053/j.gastro.2012.01.007]

Williamson RM, Price JF, Glancy S, Perry E, Nee LD, Hayes PC, Frier BM, Van Look LA, Johnston GI, Reynolds RM, Strachan MW. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. *Diabetes* 2011; 60: 1198-1206 [PMID: 21578840 DOI: 10.2337/db10-1229]

Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, Willson TM, Edwards PA. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. *Proc Natl Acad Sci USA* 2006; 103: 1006-1011 [PMID: 16410358 DOI: 10.1073/pnas.0509682103]

Zhang L, Wang YD, Chen WD, Wang X, Lou G, Liu N, Lin M, Forman BM, Huang W. Promotion of liver regeneration/repair by farnesoid X receptor in both liver and intestine in mice. *Hepatology* 2012; 56: 2336-2343 [PMID: 22711662 DOI: 10.1002/hep.25905]

Nomoto M, Miyata M, Yin S, Kurata Y, Shimada M, Yoshinari K, Gonzalez FJ, Suzuki K, Shibusaki S, Kurosawa T, Yamazoe Y. Bile acid-induced elevated oxidative stress in the absence of farnesoid X receptor. *Biol Pharm Bull* 2009; 32: 172-178 [PMID: 19182371]

Wu W, Zhu B, Peng X, Zhou M, Jia D, Gu J. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease. *Biochem Biophys Res Commun* 2014; 443: 68-73 [PMID: 24269813 DOI: 10.1016/j.bbrc.2013.11.067]

Mencarelli A, Renga B, Distrucci E, Fiorucci S. Antiatherosclerotic effect of farnesoid X receptor. *Am J Physiol Heart Circ Physiol* 2009; 296: H272-H281 [PMID: 19028791 DOI: 10.1152/ajpheart.01075.2008]
